December 2023

Groupes de patients identifiés par machine learning à partir d'une analyse groupée du programme de développement clinique du sécukinumab dans le rhumatisme psoriasique, la spondylarthrite ankylosante et le rhumatisme psoriasique avec manifestations axiales

Clin Exp Rheumatol 2023;42(3):696–701 doi: 10.55563/clinexprheumatol/b8co74

Psoriatic arthritis clusters, obtained by machine learning (ML) analysis of pooled data from the FUTURE, MEASURE, and MAXIMISE trials, indicate phenotypical heterogeneity of patients with PsA and axial manifestations and overlapping features across the spondyloarthritis spectrum. Here, Baraliakos, et al. sort to identify distinct clinical clusters, based on patient demographics and baseline clinical indicators, from the secukinumab clinical development programme.

Keywords:

October 2023

Inhibiteur de Janus Kinase-Tofacitinib associé au pemphigus : Analyse des données du système de notification des effets indésirables de la FDA

ExpExpert Opin Drug Saf. 2023;22(12):1317–1320 doi: 10.1080/14740338.2023.2248872

This study presents initial data suggesting an association between the use of JAK inhibitors and pemphigus. This research used the FAERS database to investigate connections between JAK inhibitor usage and the occurrence of pemphigus as an adverse event.

Keywords:

Incidence, prévalence et co-occurrence des troubles auto-immuns au cours du temps et en fonction de l'âge, du sexe et du statut socio-économique : Une étude de cohorte basée sur la population de 22 millions d'individus au Royaume-Uni

Lancet. 2023; 401(10391):1878–1890 doi 10.1016/S0140-6736(23)00457-9

Incidence rates for autoimmune diseases increased between 2000 and 2019 in the UK, notably in coeliac disease, Sjogren's syndrome, and Graves' disease. Pernicious anaemia and Hashimoto's thyroiditis had the greatest decrease in incidence. These disorders affected about 10% of the population, with socioeconomic, seasonal, and regional variations observed.

Keywords:

August 2023

Le filgotinib modifie les biomarqueurs des protéines du sang périphérique associés à l'inflammation chez les adultes atteints de polyarthrite rhumatoïde active et avec réponse inadéquate antérieure au méthotrexate

Rheumatol Ther. 2023;10(5):1335–1348 doi 10.1007/s40744-023-00583-9

This study by Tanaka, et al. shows that filgotinib reduces peripheral protein biomarkers associated with JAK/STAT signalling, inflammatory signalling, immune cell migration, and bone resorption in RA patients. Notably, filgotinib 200 mg significantly reduced IL-6, TNF, CXCL13 levels as early as Week 4.

Keywords:

May 2023

Evaluation of BMS-986142, a Reversible Bruton’s Tyrosine Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis: A Phase 2, Randomised, Double-blind, Dose-ranging, Placebo-controlled, Adaptive Design Study

Lancet Rheumatol 2023;5:e263–73 doi 10.1016/S2665-9913(23)00089-9

Investigators from a phase 2 study concluded that further investigation with BMS-986142 (a novel BTK) in people with RA is not necessary.

Keywords:

February 2023

Efficacité clinique d'un inhibiteur alternatif du TNF et du sécukinumab chez les patients non-répondeurs primaires et secondaires à un inhibiteur antérieur du TNF dans la spondylarthrite ankylosante

Mod Rheumatol. 2023 doi: 10.1093/mr/roac005

This study demonstrated comparable drug retention between AS patients treated with alternative TNFi and secukinumab after failing to respond to prior TNFi therapy. The objective of this study was to compare the drug retention times and clinical efficacy of alternative TNFi and secukinumab in primary and secondary
non-responders with AS.

Keywords: